急诊环境下创伤性损伤使用氨甲环酸:随机对照试验的系统评价与偏倚校正Meta分析
该研究为系统评价与偏倚校正Meta分析,检索Medline、Embase和Cochrane Central,纳入7项在急诊创伤患者中比较氨甲环酸与安慰剂的随机对照试验,主要终点为1个月死亡率,采用MASTER量表评估方法学质量并用质量效应法校正。结果显示氨甲环酸组1个月死亡风险降低(OR 0.89,95%CI 0.84–0.95),NNT为61;24小时死亡率亦降低(OR 0.76,95%CI 0.65–0.88);血管闭塞事件未见显著增加(OR 0.96,95%CI 0.73–1.27)。亚组分析提示氨甲环酸在全身创伤优于创伤性颅脑损伤,院前给药较院内给药生存获益更明显。
要点
- 急诊创伤患者使用氨甲环酸可降低1个月死亡风险(OR 0.89,95%CI 0.84–0.95),NNT为61以避免1例额外死亡。
- 氨甲环酸组24小时死亡率降低(OR 0.76,95%CI 0.65–0.88)。
- 未发现血管闭塞事件增加的有力证据(OR 0.96,95%CI 0.73–1.27)。
- 亚组分析提示院前给药较院内给药生存获益更明显,全身创伤较创伤性颅脑损伤死亡更少。
适用人群与场景
- 急诊创伤性损伤患者,纳入比较氨甲环酸与安慰剂的随机对照试验人群。
研究设计与关键结果
- 研究类型为系统评价与偏倚校正Meta分析,共纳入7项随机对照试验,检索Medline、Embase和Cochrane Central,比较氨甲环酸与安慰剂在急诊创伤中的效果。
- 主要终点1个月死亡率:氨甲环酸组死亡风险降低11%(OR 0.89,95%CI 0.84–0.95),NNT为61以避免1例额外死亡。
- 24小时死亡率:氨甲环酸组降低(OR 0.76,95%CI 0.65–0.88)。
- 血管闭塞事件:未发现增加的 compelling 证据(OR 0.96,95%CI 0.73–1.27)。
- 亚组分析:氨甲环酸在全身创伤中的效果优于创伤性颅脑损伤;院前给药较院内给药生存获益更明显。
证据类型、等级与局限
- 证据类型:系统评价与偏倚校正Meta分析,纳入7项随机对照试验,采用MASTER量表评估方法学质量并应用质量效应法校正。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急诊创伤使用氨甲环酸可降低1个月死亡率,且无显著血管闭塞事件证据;院前给药较院内给药与死亡率降低相关,全身创伤较创伤性颅脑损伤死亡更少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: Traumatic injury causes a significant number of deaths due to bleeding. Tranexamic acid (TXA), an antifibrinolytic agent, can reduce bleeding in traumatic injuries and potentially enhance outcomes. Previous reviews suggested potential TXA benefits but did not consider the latest trials.
METHODS: A systematic review and bias-adjusted meta-analysis were performed to assess TXA's effectiveness in emergency traumatic injury settings by pooling estimates from randomized controlled trials. Researchers searched Medline, Embase, and Cochrane Central for randomized controlled trials comparing TXA's effects to a placebo in emergency trauma cases. The primary endpoint was 1-month mortality. The methodological quality of the trials underwent assessment using the MASTER scale, and the meta-analysis applied the quality-effects method to adjust for methodological quality.
RESULTS: Seven randomized controlled trials met the set criteria. This meta-analysis indicated an 11% decrease in the death risk at 1 month after TXA use (odds ratio [OR] 0.89, 95% confidence interval [CI] 0.84 to 0.95) with a number needed to treat of 61 to avoid 1 additional death. The meta-analysis also revealed reduced 24-hour mortality (OR 0.76, 95% CI 0.65 to 0.88) for TXA. No compelling evidence of increased vascular occlusive events emerged (OR 0.96, 95% CI 0.73 to 1.27). Subgroup analyses highlighted TXA's effectiveness in general trauma versus traumatic brain injury and survival advantages when administered out-of-hospital versus inhospital.
CONCLUSIONS: This synthesis demonstrates that TXA use for trauma in emergencies leads to a reduction in 1-month mortality, with no significant evidence of problematic vascular occlusive events. Administering TXA in the out-of-hospital setting is associated with reduced mortality compared to inhospital administration, and less mortality with TXA in systemic trauma is noted compared with traumatic brain injury specifically.
参考来源
- Fouche PF, Stein C, Nichols M, et al. Tranexamic Acid for Traumatic Injury in the Emergency Setting: A Systematic Review and Bias-Adjusted Meta-Analysis of Randomized Controlled Trials. Ann Emerg Med. 2023. PMID: 37999653. doi:10.1016/j.annemergmed.2023.10.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。